The highly specialized division of Gynecologic Oncology is comprised of a team of skilled clinicians and researchers. The UCSF Helen Diller Family Comprehensive Cancer Center is an NCI Designated Cancer Center with active basic science, clinical and translational research programs in Women's Cancer. The division has an outstanding track record of interdisciplinary clinical care, coupled with highly productive department-based research effort.
Mission & Goals
As a clinical and academic division, we are focused on patient care, research and education.
We provide early cancer diagnosis, state of the art treatment and compassionate care
We conduct research to discover, develop, and deliver advancements in early detection, treatment and prevention of cancers of the reproductive tract
We train and inspire future leaders in gynecologic oncology and
To partner with community and national organizations in promoting cancer awareness and treatment via scholarship and policy
FacultyLee-may Chen, MD, Interim Division Chief, Professor
Dr. Chen is a specialist in gynecologic malignancies, with a particular interest in surgical and medical management of ovarian cancer. Her research focuses on early detection in women who are at a high risk of developing gynecological cancer, symptom management, decision-making in the treatment of gynecologic cancers and the effects of psychosocial support on patients. Karen Smith-McCune, MD, PhD, Professor
Dr. Smith-McCune is the director of the Dysplasia Clinic at the Helen Diller Family Comprehensive Cancer Center at the UCSF Mt. Zion campus. Her research interests are focused in abnormal pap smears, cervical pre-cancer, cervical cancer screening, Human Papilloma Virus (HPV) and vulvar disease. Rebecca Brooks, MD, Assistant Professor
Dr. Brooks' research interests are focused on genetic mechanisms underlying metastatic disease and their influence on cancer outcomes, the interaction of comorbidity and cancer, and clinical trials. Stefanie Ueda, MD, Assistant Professor
Dr. Ueda's research interests are robotic surgery, uterine cancers, biologically targeted therapies in ovarian cancer, and international health.